AAV Analytics: Driving Innovation Through Collaboration

Capabilities

A Holistic Approach to AAV Advanced Analytics

Product Characterization and QC Analytics

Recorded: May 2022

This webinar will discuss how we explore innovative AAV analytics approaches through collaborative efforts with partners such as NIBRT and Refeyn. In this session, we will cover the development of an effective digestion method, AAV mass spectrometry, and photometry.

Register to watch our webinar on-demand

You can ask your own questions of our experts.

Name(Required)

First Last

Company Name(Required)

Job Title(Required)

Country(Required)

State

Email(Required)

Thank you for registering to watch our on-demand webinar. By submitting this form, you consent to the collection and processing of your personal data by Pharmaron in accordance with our Privacy Policy. You may be contacted by email following your webinar viewing regarding any questions you may have, as well as relevant services and updates. You can unsubscribe or withdraw your consent at any time.

Key Messages on AAV Analytics:

AAV analytical challenges require innovative solutions and a diverse range of technologies to address adequately
Pepsin-based digestion provides a fast, robust, and automation-friendly approach for peptide mapping of protease-resistant AAV capsids.
Mass spectrometry of intact AAV particles offers a unique perspective on the molecules that can be used to support process development.
Mass photometry provides data on mass and E:F ratio with minimal sample preparation and rapid data acquisition and analysis

Agenda:

A diverse approach is required for comprehensive AAV analytical testing (KOL)
- AAV analytical approaches and limitations
- New technologies and applications
- Future developments
Advancing analytics and driving results through collaboration (Pharmaron)
- Collaborations – past and present
- NIBRT – AAV capsid protein digestion
- NIBRT – intact AAV mass spectrometry
- Mass Photometry – E:F ratios at a fraction of the cost
Collaboration and Beta-testing of Samux MP mass photometer (Refeyn)
- Introduction to Refeyn and mass photometry
- Presentation of Pharmaron Beta testing data
- Presentation of Internal Pharmaron data

Meet our Speakers

Key Opinion Leader:

Tony Bou Kheir – Head of Analytical Development and QC at Purespring Therapeutics

Tony Bou Kheir leads the analytical development and QC program at Purespring Therapeutics, developing new analytics to support product characterization and release. Tony has over 10 years of experience in designing, developing, and applying novel analytics to support product characterization. Tony leads a team focused on improving AAV manufacture through the design and application of new technologies for in-process testing and the development of more accurate and robust assays for product release. Tony’s team also oversees assay qualification and technology transfer to 3rd party GMP facilities and CDMOs.

Speakers:

Ian Anderson, Ph.D. – Associate Director, Analytical Sciences at Pharmaron Gene Therapy

Ian Anderson is Associate Director of Analytical Sciences at Pharmaron Gene Therapy and is responsible for leading the Physicochemical Characterisation group that develops methods for the analysis of AAV. Ian has over 12 years of experience developing and applying novel analytics to support gene therapy product characterization. Ian has led multiple external collaborations at Pharmaron, focusing on improving AAV analytics to support AAV manufacturing processes. Ian completed his PhD in MET Receptor Signalling in 2009, and subsequent Post-doctoral studies focused on Lentivirus at University College London before moving into Industry.

Gareth Rogers – Product Manager at Refeyn

Gareth Rogers is a Product Manager at Refeyn, a company specializing in developing and manufacturing instrumentation for biomolecular characterization using mass photometry. As a member of the Refeyn product management team, he is jointly responsible for developing and deploying mass photometry systems designed to meet the needs of the biopharmaceutical industry. Before joining Refeyn, he worked for several leading photonics companies in varied roles, from technology scouting to sales and the development of advanced imaging systems. Gareth has a PhD in Molecular Physiology and spent several years as a postdoctoral research scientist at the University of Cambridge, specializing in studying the molecular mechanisms behind the secretion of insulinotropic polypeptides to explore the pathophysiology underlying many metabolic diseases, including diabetes.

AAV Analytics: Driving Innovation through Collaboration